Testing Vitamin B6 for sensory reactivity in autism
Testing the Potential of High-dose Vitamin B6 Supplements for Sensory Reactivity in Autism
This study is testing if high doses of Vitamin B6 can help autistic adults feel less anxious and sensitive to sensory input.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | University of Reading Academic / other |
| Locations | 1 site (Reading) |
| Trial ID | NCT06234501 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of high-dose Vitamin B6 supplementation on sensory hyperreactivity and anxiety in autistic adults. Participants will be divided into two groups, one receiving Vitamin B6 and the other a placebo, to assess differences in sensory reactivity and anxiety levels. Additionally, the study will evaluate the impact of Vitamin B6 on sleep quality, ADHD scores, and visual perception tasks related to GABAergic activity. The goal is to determine if Vitamin B6 can improve these aspects of autism.
Who should consider this trial
Good fit: Ideal candidates for this study are autistic adults aged 18 to 60.
Not a fit: Patients who are taking supplements with more than 2mg of Vitamin B6 or GABA agonist drugs may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new, non-invasive treatment option for reducing sensory hyperreactivity and anxiety in autistic individuals.
How similar studies have performed: While there is limited research on high-dose Vitamin B6 for autism, similar studies exploring nutritional interventions have shown promise, making this approach potentially novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Between the ages of 18 to 60 * With a diagnosis of autism Exclusion Criteria: * Taking any supplement that contains more than 2mg of Vitamin B6 or taking GABA agonist drugs * Have a medical history of peripheral neuropathy * lactose intolerance (placebo tablet is lactose based)
Where this trial is running
Reading
- University of Reading — Reading, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Dr David T Field, PhD — University of Reading
- Study coordinator: Dr David T Field, PhD
- Email: d.t.field@reading.ac.uk
- Phone: +441183785004
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.